文献速递免疫规划卫生政策与健康促进

构建世界卫生组织疫苗政策证据考量(ECVP)概念:以面向成人和青少年的结核病疫苗为测试案例

Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case.
PubMed 文献 · Vaccine · 2022-02-11

目前尚无正式机制在疫苗候选者临近监管批准前告知开发者全球政策推荐所需证据,可能导致引入延迟。世界卫生组织正在评估新战略对齐工具ECVP的价值,旨在早期提供支持政策决策的临床试验和观察性数据预期信息。以面向成人和青少年的结核病疫苗为测试案例,开发首个ECVP考量指南。

要点

  • ECVP旨在疫苗3期研究设计前提供预期证据信息,以支持世界卫生组织或政策决策。
  • ECVP不会取代世界卫生组织免疫战略咨询专家组对所有疫苗要求的证据到推荐过程。
  • 面向成人和青少年的结核病疫苗被用作测试案例,以开发首个ECVP考量指南。

核心结论

  • 世界卫生组织正在评估ECVP作为战略对齐工具的价值,以填补当前证据需求信息缺口,并可能减少疫苗推荐与使用之间的延迟。

研究设计与样本

  • 本文为世界卫生组织对ECVP概念评估的描述性文件,以面向成人和青少年的结核病疫苗作为测试案例。

主要发现

  • 目前尚无正式机制或系统方法在疫苗候选者临近监管批准前告知开发者全球政策推荐所需证据。
  • ECVP旨在提供早期(3期研究设计前)关于预期临床试验和观察性数据或证据的信息,以支持世界卫生组织或政策决策。
  • ECVP不会取代世界卫生组织免疫战略咨询专家组对所有寻求世界卫生组织政策推荐的疫苗所需的证据到推荐过程。

临床怎么用

  • ECVP旨在为疫苗开发者、资助者和其他关键利益相关者提供信息,促进其晚期疫苗开发战略规划中的对齐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Currently, no formal mechanisms or systematic approaches exist to inform developers of new vaccines of the evidence anticipated to facilitate global policy recommendations, before a vaccine candidate approaches regulatory approval at the end of pre-licensure efficacy studies. Consequently, significant delays may result in vaccine introduction and uptake, while post-licensure data are generated to support a definitive policy decision. To address the uncertainties of the evidence-to-recommendation data needs and to mitigate the risk of delays between vaccine recommendation and use, WHO is evaluating the need for and value of a new strategic alignment tool: Evidence Considerations for Vaccine Policy (ECVP). EVCPs aim to fill a critical current gap by providing early (pre-phase 3 study design) information on the anticipated clinical trial and observational data or evidence that could support WHO and/or policy decision making for new vaccines in priority disease areas. The intent of ECVPs is to inform vaccine developers, funders, and other key stakeholders, facilitating stakeholder alignment in their strategic planning for late stage vaccine development. While ECVPs are envisaged as a tool to support dialogue on evidence needs between regulators and policy makers at the national, regional and global level, development of an ECVP will not preclude or supersede the independent WHO's Strategic Advisory Group of Experts on Immunization (SAGE) evidence to recommendation (EtR) process that is required for all vaccines seeking WHO policy recommendation. Tuberculosis (TB) vaccine candidates intended for use in the adolescent and adult target populations comprise a portfolio of priority vaccines in late-stage clinical development. As such, TB vaccines intended for use in this target population provide a 'test case' to further develop the ECVP concept, and develop the first WHO ECVP considerations guidance.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kochhar S, Barreira D, Beattie P, et al. Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case. Vaccine. 2022. PMID: 35164990. doi:10.1016/j.vaccine.2021.10.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。